Article Text

Download PDFPDF
Original research
A novel angiographic classification for the endovascular recanalization of symptomatic nonacute extracranial vertebral artery occlusion
  1. Feng Gao1,
  2. Hongbo Zheng2,
  3. Xu Guo3,
  4. Xuan Sun1,
  5. Zhongrong Miao1
  1. 1Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Beijing, China
  2. 2Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
  3. 3Department of Interventional Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
  1. Correspondence to Dr Feng Gao, Department of Interventional Neuroradiology, Beijing Tiantan Hospital Department of Interventional Neuroradiology, Beijing 100070, China; gaofengletter{at}sina.com

Abstract

Background There remains major uncertainty regarding the optimal therapy for symptomatic nonacute extracranial vertebral artery occlusion (EVAO). Endovascular recanalization for EVAO is technically challenging, and limited data are available. This research aimed to report a multicenter clinical experience of endovascular recanalization for symptomatic nonacute EVAO and establish a novel angiographic classification.

Methods From June 2011 to December 2019, 50 symptomatic nonacute EVAO patients treated with endovascular recanalization in three regional referral stroke centers were retrospectively analyzed. All patients were categorized into four groups based on the angiographic classification. The rates of technical success, periprocedural complications, any stroke or death within 1 month, and follow-up data were assessed.

Results The rates of technical success, periprocedural complications, and any stroke or death within 1 month were 86.0% (43/50), 12.0% (6/50), and 4.0% (2/50), respectively. The recanalization rates gradually decreased from Type A to Type D (100%, 94.7%, 80%, and 63.6%, respectively; P=0.007). The EVAO patients in the Type A group with tapered stump and short-segment occlusions showed excellent recanalization effects, with 100% technical success rates and no complications. Conversely, the lowest recanalization rate of 63.6% (7/11) and the highest periprocedural complication rate of 27.3% (3/11) were observed for the Type D group.

Conclusions Endovascular recanalization for symptomatic nonacute EVAO is technically feasible, especially Type A EVAO patients, which can provide an alternative treatment option for recurrent vertebrobasilar ischemia despite optimal medical therapy. The angiographic categorization established in this study is conducive to the selection of suitable patients prior to treatment decision.

  • angiography
  • angioplasty
  • atherosclerosis
  • stent
  • stroke

Statistics from Altmetric.com

Footnotes

  • FG and HZ contributed equally.

  • Contributors Feng Gao, MD; study concept and design, study conduct, draft paper, critical revision of manuscript. Hongbo Zheng, MD; study concept and design, study conduct, draft paper, critical revision of manuscript. Feng Gao and Hongbo Zheng contributed equally to this work. Xu Guo, MD; study conduct, acquisition of data, statistical analysis. Xuan Sun, MD; study conduct, acquisition of data. Zhongrong Miao, MD; study conduct, critical revision of manuscript.

  • Funding This study was funded by National Key R&D Program (2018AAA0102600).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The retrospective study was approved by the Institutional Review Board of Beijing Tiantan hospital (KY 2020-115-01), and the requirement for patient informed consent was waived for review of patient records and images.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request. The manuscript has not been fully published or submitted elsewhere. Our corresponding author takes full responsibility for the data, the analyses, and interpretation, and the conduct of the research.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.